» Articles » PMID: 16873729

Nuclear Receptors Nur77, Nurr1, and NOR-1 Expressed in Atherosclerotic Lesion Macrophages Reduce Lipid Loading and Inflammatory Responses

Overview
Date 2006 Jul 29
PMID 16873729
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Atherosclerosis is an inflammatory disease in which macrophage activation and lipid loading play a crucial role. In this study, we investigated expression and function of the NR4A nuclear receptor family, comprising Nur77 (NR4A1, TR3), Nurr1 (NR4A2), and NOR-1 (NR4A3) in human macrophages.

Methods And Results: Nur77, Nurr1, and NOR-1 are expressed in early and advanced human atherosclerotic lesion macrophages primarily in areas of plaque activation/progression as detected by in situ-hybridization and immunohistochemistry. Protein expression localizes to the nucleus. Primary and THP-1 macrophages transiently express NR4A-factors in response to lipopolysaccharide and tumor necrosis factor alpha. Lentiviral overexpression of Nur77, Nurr1, or NOR-1 reduces expression and production of interleukin (IL)-1beta and IL-6 proinflammatory cytokines and IL-8, macrophage inflammatory protein-1alpha and -1beta and monocyte chemoattractant protein-1 chemokines. In addition, NR4A-factors reduce oxidized-low-density lipoprotein uptake, consistent with downregulation of scavenger receptor-A, CD36, and CD11b macrophage marker genes. Knockdown of Nur77 or NOR-1 with gene-specific lentiviral short-hairpin RNAs resulted in enhanced cytokine and chemokine synthesis, increased lipid loading, and augmented CD11b expression, demonstrating endogenous NR4A-factors to inhibit macrophage activation, foam-cell formation, and differentiation.

Conclusions: NR4A-factors are expressed in human atherosclerotic lesion macrophages and reduce human macrophage lipid loading and inflammatory responses, providing further evidence for a protective role of NR4A-factors in atherogenesis.

Citing Articles

NR4A1 deficiency promotes carotid plaque vulnerability by activating integrated stress response via targeting Bcat1.

Chen L, Shi Y, Xiao D, Huang Y, Jiang Y, Liang M Cell Mol Life Sci. 2025; 82(1):91.

PMID: 39985585 PMC: 11846829. DOI: 10.1007/s00018-025-05602-2.


The endocannabinoid anandamide prevents TH17 programming of activated T lymphocytes while preserving TH1 responses.

Kiprina A, Teichmann T, Gimenez V, Xu W, Sailer F, Windbergs M Front Pharmacol. 2025; 15:1528759.

PMID: 39759451 PMC: 11695368. DOI: 10.3389/fphar.2024.1528759.


The endocannabinoid anandamide mediates anti-inflammatory effects through activation of NR4A nuclear receptors.

Teichmann T, Pfluger-Muller B, Gimenez V, Sailer F, Dirks H, Zehr S Br J Pharmacol. 2024; 182(5):1164-1182.

PMID: 39563075 PMC: 11790392. DOI: 10.1111/bph.17366.


Inflammatory, metabolic, and sex-dependent gene-regulatory dynamics of microglia and macrophages in neonatal hippocampus after hypoxia-ischemia.

Di Martino E, Ambikan A, Ramskold D, Umekawa T, Giatrellis S, Vacondio D iScience. 2024; 27(4):109346.

PMID: 38500830 PMC: 10945260. DOI: 10.1016/j.isci.2024.109346.


Natural products and synthetic analogs as selective orphan nuclear receptor 4A (NR4A) modulators.

Safe S Histol Histopathol. 2023; 39(5):543-556.

PMID: 38116863 PMC: 11267491. DOI: 10.14670/HH-18-689.